Short answer
Parabilis Medicines Inc (PBLS) filed an 8-K current report with the SEC on September 15, 2026 reporting Item 7.01 (Regulation FD Disclosure). Updated Phase 1/2 zolucatetide data planned for oral presentation at ESMO Congress 2026.
Parabilis Medicines Inc 8-K event analysis
AI summary of each reported item and its exhibits
Item 7.01 · Regulation FD Disclosure
- Updated Phase 1/2 zolucatetide data planned for oral presentation at ESMO Congress 2026
- Data concern patients with desmoid tumors, a key clinical development milestone
- Presentation scheduled October 24 at 2:45pm CEST in Madrid during a sarcoma-focused session
- Investors may assess efficacy and safety results for implications on zolucatetide’s development path
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Parabilis Medicines Inc 8-K filings
Get the next PBLS 8-K as it lands
Follow PBLS for push alerts, or ask the research agent what this filing means.